A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors

Filiz Yavaşoğlu; Çiğdem Özdemir; Yiğit Şenol; Hacer Demir; Meltem Baykara

Makale detayları

A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors

Yazarlar:

Filiz Yavaşoğlu | Çiğdem Özdemir | Yiğit Şenol | Hacer Demir | Meltem Baykara

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.45 Issue 6, pp.853-861

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298432

pISSN:

1305-4953

Anahtar kelimeler:

Özet:

 The incidence of cancer is increasing in the world. With the developments in cancer treatment, the life expectancy of patients is prolonged and the incidence of secondary malignancies is increasing. We retrospetively patients with syncronous  metachronous oncological malignancies accompanying hematological malignancies in a newly established hematology center. Data were obtained from the medical records. Demographic data, treatments and overall survival of the patients were evaluated. Twenty eight 6 of 433 patients hematological malignancies were included in the study. 12 patients 42.9 were diagnosed with syncronous and 16 57.1 patients with metachronous hematologic-oncologic tumors. Sixteen of the patients were male,twelve were female. In syncronous tumors, the most common hematologic malignancy was Non-hodgkın lymphoma NHL, while the most common oncologic malignancies were thyroid papillary cancer and colon cancer. In metachronous tumors, the most common malignancies were NHL and breast cancer. The median time between diagnosis of metachronous tumors was 49.5 months 8-192 months. The median survival of patients with syncronous malignancies was 19 months SE12.19 95 CI 0-42.89, with metachronous malignancies was 22 months SE14.0 95 CI 0-49.44. There was no statistically significant difference in the comparison of survival curves of patients with syncronous and metachronous malignancies p0.382. Oncological malignancies accompanying hematological malignancies are not uncommon. There is no standart treatment for syncronous  metachronous hematologic malignancies. In the presence of syncronous multipl malignancies should be evaluated individually.

 The incidence of cancer is increasing in the world. With the developments in cancer treatment, the life expectancy of patients is prolonged and the incidence of secondary malignancies is increasing. We retrospetively patients with syncronous  metachronous oncological malignancies accompanying hematological malignancies in a newly established hematology center. Data were obtained from the medical records. Demographic data, treatments and overall survival of the patients were evaluated. Twenty eight 6 of 433 patients hematological malignancies were included in the study. 12 patients 42.9 were diagnosed with syncronous and 16 57.1 patients with metachronous hematologic-oncologic tumors. Sixteen of the patients were male,twelve were female. In syncronous tumors, the most common hematologic malignancy was Non-hodgkın lymphoma NHL, while the most common oncologic malignancies were thyroid papillary cancer and colon cancer. In metachronous tumors, the most common malignancies were NHL and breast cancer. The median time between diagnosis of metachronous tumors was 49.5 months 8-192 months. The median survival of patients with syncronous malignancies was 19 months SE12.19 95 CI 0-42.89, with metachronous malignancies was 22 months SE14.0 95 CI 0-49.44. There was no statistically significant difference in the comparison of survival curves of patients with syncronous and metachronous malignancies p0.382. Oncological malignancies accompanying hematological malignancies are not uncommon. There is no standart treatment for syncronous  metachronous hematologic malignancies. In the presence of syncronous multipl malignancies should be evaluated individually.

 The incidence of cancer is increasing in the world. With the developments in cancer treatment, the life expectancy of patients is prolonged and the incidence of secondary malignancies is increasing. We retrospetively patients with syncronous  metachronous oncological malignancies accompanying hematological malignancies in a newly established hematology center. Data were obtained from the medical records. Demographic data, treatments and overall survival of the patients were evaluated. Twenty eight 6 of 433 patients hematological malignancies were included in the study. 12 patients 42.9 were diagnosed with syncronous and 16 57.1 patients with metachronous hematologic-oncologic tumors. Sixteen of the patients were male,twelve were female. In syncronous tumors, the most common hematologic malignancy was Non-hodgkın lymphoma NHL, while the most common oncologic malignancies were thyroid papillary cancer and colon cancer. In metachronous tumors, the most common malignancies were NHL and breast cancer. The median time between diagnosis of metachronous tumors was 49.5 months 8-192 months. The median survival of patients with syncronous malignancies was 19 months SE12.19 95 CI 0-42.89, with metachronous malignancies was 22 months SE14.0 95 CI 0-49.44. There was no statistically significant difference in the comparison of survival curves of patients with syncronous and metachronous malignancies p0.382. Oncological malignancies accompanying hematological malignancies are not uncommon. There is no standart treatment for syncronous  metachronous hematologic malignancies. In the presence of syncronous multipl malignancies should be evaluated individually.

 Dünyada kanser görülme sıklığı giderek artmaktadır. Kanser tedavisindeki gelişmelerle birlikte hastaların ortalama yaşam süreleri uzamakta ve sekonder malignitelerin görülme sıklığı artmaktadır. Yeni kurulan bir hematoloji merkezinde hematolojik malignitelere eşlik eden senkron  metakron maligniteleri retrospektif olarak inceledik.Veriler tıbbi kayıtlardan elde edildi.Hastaların demografik verileri, tedavileri ve genel sağ kalımları değerlendirildi. Hematolojik maligniteli 433 hastanın 28i 6 çalışmaya devam edildi. 12 hasta 42,9 senkron, 16 57,1 hasta ise metakron hematolojik-onkolojik tümör tanısı almıştır. Hastaların 16sı erkek, 12si kadındı. Senkron tümörlerde en sık görülen hematolojik malignite non-hodgkın lenfoma NHL, en sık görülen onkolojik maligniteler ise tiroid papiller kanseri ve kolon kanseri idi. Metakron tümörlerde en sık görülen maligniteler NHL ve meme kanseri idi. Metakron tümörlerin tanısı arasındaki medyan süre 49,5 aydı 8-192 ay. Senkron malignitesi olan hastalrın medyan sağkalımı 19 aydı SE12,19 95 CI 0-42,89, metakron maligniteleri olan hastaların medyan sağkalımı 22 aydı SE14,9 95 CI 0-49,44. Senkron ve metakron maligniteleri olan hastaların sağkalım eğrilerinin karşılaştırılmasında istatistiksel olarak anlanmlı fark saptanmadı p0,382. Hematolojik malignitelere eşlik eden onkolojik maligniteler nadir değildir. Senkron  metakron hematolojik maligniteler için standart bir tedavi yoktur. Senkron multipl malignite varlığında, malignitelerin her biri ayrı ayrı değerlendirilmelidir.

Makale detayları

A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors

Yazarlar:

Filiz Yavaşoğlu | Çiğdem Özdemir | Yiğit Şenol | Hacer Demir | Meltem Baykara

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.45 Issue 6, pp.853-861

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298432

pISSN:

1305-4953

Multipl primary neoplasms

Syncronous neoplasms

Hematologic malignanciesMultipl primer tümörler

Senkronize tümörler

Hematolojik maligniteler

Sayı

Makale detayları

A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors

Yazarlar: Filiz Yavaşoğlu | Çiğdem Özdemir | Yiğit Şenol | Hacer Demir | Meltem Baykara

Yayıncı: Eskişehir Osmangazi University

Ana Başlıklar: İç Hastalıkları

Dergi: Osmangazi Tıp Dergisi Vol.45 Issue 6, pp.853-861

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001298432

pISSN: 1305-4953

Multipl primary neoplasms

Syncronous neoplasms

Hematologic malignanciesMultipl primer tümörler

Senkronize tümörler

Hematolojik maligniteler

Sayı

Yazarlar:

Filiz Yavaşoğlu | Çiğdem Özdemir | Yiğit Şenol | Hacer Demir | Meltem Baykara

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.45 Issue 6, pp.853-861

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298432

pISSN:

1305-4953